latest news releases from the newsroom
Westinghouse Solar, Inc.
Akeena Solar Revises 2008 Revenue Growth Rate Guidance
LOS GATOS, Calif., Dec. 16, 2008 (GLOBE NEWSWIRE) -- Akeena Solar, Inc. (Nasdaq:AKNS), a leading designer and installer of solar power systems, today issued revised guidance for the fiscal year ending December 31, 2008. Due to delayed installations at a few large commercial projects, the company now anticipates 2008 annual revenue growth to be in the range of 25% - 30% over 2007. Previously, management had estimated year-over-year revenue growth in 2008 to be between 30% - 40%.
LTX-Credence Introduces New DC and Power Option for X-Series Test Systems
MILPITAS, Calif., Dec. 16, 2008 (GLOBE NEWSWIRE) -- LTX-Credence Corporation (Nasdaq:LTXC), a global provider of focused, cost-optimized ATE solutions, today announced the addition of its Quad Floating VI (QFVI) option for its X-Series test platform. The QFVI addresses critical requirements for cost effective testing of advanced power management and automotive applications, such as battery charging and management, high side and full bridge switch networks and a broad range of brake, airbag, ignition and motor controllers.
Arasan Chip Systems, Inc.
Arasan Chip Systems First to Provide End-to-End Solution with MIPI D-PHY IP
SAN JOSE, Calif., Dec. 16, 2008 (GLOBE NEWSWIRE) -- Arasan Chip Systems, Inc., "Arasan" a leader in Intellectual Property (IP) solutions - IP cores, Verification IP (VIP), Software Drivers and Stacks and Hardware Solutions, announced the immediate availability of the silicon-proven Mobile Industry Processor Interface (MIPI(sm)) D-PHY IP, for use with Display Serial Interface (DSI), Camera Serial Interface (CSI), and UniPro(sm) protocol. As a leading provider of mobile IP, Arasan continues to strengthen its strategic mobile initiative by expanding the MIPI IP portfolio with physical analog IP, therefore enabling a complete and comprehensive MIPI solution.
Nymox Pharmaceutical Corporation
Nymox Releases New Study Data From U.S. Study of NX-1207 for Benign Prostatic Hyperplasia Which Shows Significantly Less Interruption of Sleep for Men Given Nymox Drug
HASBROUCK HEIGHTS, N.J., Dec. 16, 2008 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced new results from a recently completed multi-center U.S. clinical study of NX-1207, the Company's innovative investigational drug for benign prostatic hyperplasia (BPH). The evidence indicates that NX-1207 can markedly reduce the incidence of nocturia, a particularly bothersome symptom of nighttime urination associated with BPH. After 90 days, subjects treated with a therapeutic dose of NX-1207 had a mean 49% reduction in nocturia symptoms, which was statistically significant compared to baseline (p less than .001).